Re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status” by Yamamoto et al.
Restricted accessResearch articleFirst published online March, 2024
Re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status” by Yamamoto et al.
YamamotoM, MiyauchiA, ItoY, et al.Active surveillance outcomes of patients with low-risk papillary thyroid microcarcinoma according to levothyroxine treatment status. Thyroid, 2023; 33(10):1182–1189; doi: 10.1089/thy.2023.0046
2.
Feldt-RasmussenU, EffraimidisG, BliddalS, et al.Risks of suboptimal and excessive thyroid hormone replacement across ages. J Endocrinol Invest, 2023; In Press; doi: 10.1007/s40618-023-02229-7
3.
WändellP, CarlssonAC, LiX, et al.Levothyroxine treatment is associated with an increased relative risk of overall and organ specific incident cancers—A cohort study of the Swedish population. Cancer Epidemiol, 2020; 66:101707; doi: 10.1016/j.canep.2020.101707
4.
SugitaniI, FujimotoY, YamadaK. Association between serum thyrotropin concentration and growth of asymptomatic papillary thyroid microcarcinoma. World J Surg, 2014; 38(3):673–678; doi: 10.1007/s00268-013-2335-8
5.
ItoY, MiyauchiA, FujishimaM, et al.Thyroid-stimulating hormone, age, and tumor size are risk factors for progression during active surveillance of low-risk papillary thyroid microcarcinoma in adults. World J Surg, 2023; 47(2):392–401; doi: 10.1007/s00268-022-06770-z
